Carlos Cordon-Cardo

Carlos Cordon-Cardo

Auto-generated profile, based on publicly available information

Carlos Cordon-Cardo

Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
DVDiane Marie Del Valle
Diane Marie Del Valle
SKSeunghee Kim-Schulze
Seunghee Kim-Schulze
HHHsin-Hui Huang
Hsin-Hui Huang
NBNoam D. Beckmann
Noam D. Beckmann
SNSharon Nirenberg
Sharon Nirenberg
SGSacha Gnjatic
Sacha Gnjatic

4 December 2020 in Science
Verified
Journal Article
Open access
PDF file
AWAnia Wajnberg
Ania Wajnberg
FAFatima Amanat
Fatima Amanat
AFAdolfo Firpo
Adolfo Firpo
DADeena R. Altman
Deena R. Altman
MBMark J. Bailey
Mark J. Bailey
CCCarlos Cordon-Cardo
Carlos Cordon-Cardo
SARS-CoV-2 antibodies persist: As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al. used a cohort of more than 30,000 infected individuals with mild to moderate COVID-19 symptoms to determine the robustness and longevity of the anti–SARS-CoV-2 antibody response. They found that neutralizing antibody titers against the SARS-CoV-2 spike protein persisted for at least 5 months after infection. Although continued monitoring of this cohort will be needed to confirm the longevity and potency of this response, these preliminary results suggest that the chance of reinfection may be lower than is currently feared. Science , this issue p. 1227

1 September 2020 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
EPElisabet Pujadas
Elisabet Pujadas
FCFayzan Chaudhry
Fayzan Chaudhry
RMRussell McBride
Russell McBride
FRFelix Richter
Felix Richter
SZShan Zhao
Shan Zhao
CCCarlos Cordon-Cardo
Carlos Cordon-Cardo

1 September 2012 in Cancer Cell
Verified
Journal Article
Closed access
JDJosep Domingo-Domenech
Josep Domingo-Domenech
SVSamuel J. Vidal
Samuel J. Vidal
VRVeronica Rodriguez-Bravo
Veronica Rodriguez-Bravo
MCMireia Castillo-Martin
Mireia Castillo-Martin
SQS. Aidan Quinn
S. Aidan Quinn
CCCarlos Cordon-Cardo
Carlos Cordon-Cardo

15 January 2018 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MCMing Chen
Ming Chen
JZJiangwen Zhang
Jiangwen Zhang
KSKatia Sampieri
Katia Sampieri
JCJohn G Clohessy
John G Clohessy
LMLourdes Mendez
Lourdes Mendez
PPPier Paolo Pandolfi
Pier Paolo Pandolfi

29 August 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
LWLi Wang
Li Wang
ASAbdel Saci
Abdel Saci
PSPeter M. Szabo
Peter M. Szabo
SCScott D. Chasalow
Scott D. Chasalow
MCMireia Castillo-Martin
Mireia Castillo-Martin
MGMatthew D. Galsky
Matthew D. Galsky
Cancers infiltrated with T-cells are associated with a higher likelihood of response to PD-1/PD-L1 blockade. Counterintuitively, a correlation between epithelial–mesenchymal transition (EMT)-related gene expression and T-cell infiltration has been observed across tumor types. Here we demonstrate, using The Cancer Genome Atlas (TCGA) urothelial cancer dataset, that although a gene expression-based measure of infiltrating T-cell abundance and EMT-related gene expression are positively correlated, these signatures convey disparate prognostic information. We further demonstrate that non-hematopoietic stromal cells are a major source of EMT-related gene expression in bulk urothelial cancer transcriptomes. Finally, using a cohort of patients with metastatic urothelial cancer treated with a PD-1 inhibitor, nivolumab, we demonstrate that in patients with T-cell infiltrated tumors, higher EMT/stroma-related gene expression is associated with lower response rates and shorter progression-free and overall survival. Together, our findings suggest a stroma-mediated source of immune resistance in urothelial cancer and provide rationale for co-targeting PD-1 and stromal elements.